Amazon CEO Says Generative AI Could Be Largest Technological Transformation Since the Internet

In his letter to shareholders, Andy Jassy says Amazon is committed to cost-cutting while also investing heavily in AI. 


 
Netflix Needs to Put on Another Big Subscriber Show

The streaming giant began a crackdown on password sharing last year, and investors are getting their hopes up for another subscriber-growth bonanza this year. 


 
Banks Start Reporting Earnings This Week. Here's What To Expect.

Big lenders raked in record profits in 2023, but are dealing with growing pressures this year. 


 
Publicis Flags Tech Rebound as Revenue Growth Beats Expectations

Publicis reported a 5.3% rise in first-quarter revenue, helped by new business wins and what it called a clear rebound in the technology sector. 


 
X Received Inquiry From U.S. Lawmakers on Brazil Actions, Musk Says

Social-media platform X has received an inquiry from U.S. lawmakers related to the company's continuing legal standoff with Brazilian authorities, Elon Musk said. 


 
Lufthansa Halts Tehran Flights After U.S. Warns of Imminent Attack on Israel by Iran

Lufthansa has halted flights to and from Tehran due to heightened security risks in the Middle East after the U.S. warned of possible Iranian attacks on Israel. 


 
Singapore's Temasek Plans to Boost Investments in Europe

Singapore's state-investment company Temasek plans to invest more in European companies focused on sustainability, pharmaceuticals and biotechnology to build up resilience in its portfolio. 


 
Uniqlo Owner Raises Profit Forecast

Fast Retailing reported profit growth for the fiscal first half, driven by higher sales in the U.S. and Europe, a sign of success in its strategy of global expansion. 


 
Netflix Stock Deserves a Place in the Magnificent 7

It's set to report its first-quarter earnings on April 18, and it's still reasonably priced. Investors should pay attention. 


 
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

The deal would give the pharmaceutical giant access to Alpine's potential treatment for chronic kidney disease.


(END) Dow Jones Newswires

04-11-24 0715ET